Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Innovative Medical

Criteria

Inclusion Criteria:

• Ability to provide informed consent, complete questionnaires, and likely to complete all visits

• Subject must be male or female, of any race, and at least 21 years old

• Undergoing uncomplicated cataract surgery with clear corneal incisions

Exclusion Criteria:

• Subjects with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course

• Acute or chronic disease or illness that would increase risk or confound study results (e.g., uncontrolled diabetes mellitus, immunocompromised,etc.)

• Uncontrolled systemic disease

• Corneal abnormalities (e.g., stromal, epithelial or endothelial dystrophies)

• Subjects who use concurrent topical or systemic medications that may impair healing, including but not limited to:antimetabolites,isotretinoin (Accutane) within 6 months of treatment, and amiodarone hydrochloride (Cordarone) within 12 months of treatment

• Subjects with a history of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or simplex, endocrine disorders (including but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis

• Concurrent participation or participation in the last 30 days in any other clinical trial